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Amanda Jensen 
HYDROGEN SULFIDE THERAPY IMPROVES INTESTINAL RECOVERY 
THROUGH ENDOTHELIAL NITRIC OXIDE DEPENDENT MECHANSISMS 
 
 H2S is a gaseous mediator that acts as an anti-inflammatory agent 
contributing to gastrointestinal mucosal defense.  It promotes vascular dilation, 
mucosal repair, and resolution of inflammation following intestinal ischemia and 
may be exploited as a novel therapeutic agent.   It is unclear if H2S works 
through nitric oxide-dependent pathways in the intestine.  We appreciated that 
H2S was able to improve post-ischemic recovery of mesenteric perfusion, 
mucosal integrity, and inflammation.  The beneficial effects of H2S appear to be 
mediated through endothelial nitric oxide-dependent pathways. 
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CHAPTER ONE: INTRODUCTION 
1.1 Mesenteric Ischemia 
Acute mesenteric ischemia (AMI) continues to be a devastating intra-abdominal 
emergency with mortality as high as 60-80% [1]. It is caused by either 1) a sudden acute 
arterial occlusion, 2) a venous occlusion or 3) a sudden drop in circulating pressure. 
During hypoperfusion, this insufficient blood flow within the mesenteric circulation is 
unable to meet intestinal metabolic demands and often this may lead to mesenteric 
infarction and intestinal necrosis. Patients who remain untreated can quickly 
decompensate and progress to shock, multi-system organ failure and death [2]. The 
most critical factor that continues to impact outcomes in patients is the time to diagnosis 
and intervention.  
Major etiologies of intestinal ischemia include arterial obstruction with embolic 
occlusion (40-50%), arterial thrombotic occlusion (15-25%), and venous thrombosis (5%) 
with the remaining due to non-occlusive ischemia that causes intestinal hypoperfusion 
[3-5]. This disease affects multiple patient populations with varying ages and 
comorbidities and accounts for about 0.1% of all hospital admissions [5].  
If patients survive these ischemic episodes, they are often faced with prolonged 
hospitalization and long term parenteral nutrition needs [6]. Additionally, reported overall 
survival at one, three and five years following surgery for AMI has been found to be 
26%, 23%, and 21% respectively [7]. Early diagnosis and aggressive therapy may 
significantly reduce the morbidity and mortality of this life-threatening disease. While 
clinical studies emphasize diagnostic and therapeutic algorithms to expedite treatment 
for the diagnosis of AMI, the disease prognosis remains dismal. To that end, noteworthy 
advancements in the medical treatment of intestinal ischemia within the last decade 
have been sparse and a novel therapeutic option for the treatment of intestinal ischemia 
is of the utmost importance.  
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1.2 Hydrogen Sulfide 
 
Hydrogen sulfide (H2S) has recently been identified as a potential therapeutic 
strategy for gastrointestinal disease. H2S donors have been found to be cytoprotective in 
the setting of NSAID-induced intestinal injury through modulation of the bile and the 
microbiome [8, 9]. Additionally, in the setting of colitis, endogenous H2S production 
increases and is found to decrease following resolution of colitis, while exogenous 
application also causes significant reduction in the severity of colitis [10].  
H2S has also been found to be of benefit in intestinal IR injury. Pre-conditioning with 
an H2S donor prior to intestinal ischemia has been found to prevent mitochondrial 
dysfunction by a BKCa channel-dependent mechanism [11]. In the post-ischemic period, 
application of an H2S donor decreases apoptosis and preserves intestinal architecture 
[12]. Other I/R-related injuries including myocardial infarction, cerebral ischemia, and 
transplant associated renal ischemia have also observed therapeutic benefit and end-
organ protection with use of H2S donors  [13-16]. H2S likely plays an important role 
physiologically through cellular signaling and vasodilation.  Additionally, it exhibits anti-
inflammatory, anti-oxidant and anti-apoptotic effects [11, 12, 17] (Figure 1).  
 
Figure 1. Protective Effects of H2S 
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1.3 Mechanisms of Action 
Hydrogen sulfide is a gaseous mediator that acts as an anti-inflammatory agent 
contributing to gastrointestinal mucosal defense.  It promotes vascular dilation, mucosal 
repair, and resolution of inflammation following intestinal ischemia.H2S may work 
through endothelial nitric oxide synthase (eNOS) to bring about its protective effects by 
increasing the production of nitric oxide; a known vasodilator. H2S can donate a sulfur 
moiety to a cysteine on eNOS which then promotes its dimerization [18] (Figure 2).  Only 
once dimerized can eNOS facilitate the production of nitric oxide [19].  Nitric oxide, as a 
downstream effector, may then promote vascular dilation[20].   
Other studies on coronary artery physiology have suggested that hydrogen sulfide 
may exert its effects through both nitric oxide-dependent and nitric oxide-independent 
pathways, depending on native vascular tonicity [21].  Testai et al. specifically 
demonstrated that in normotensive rats, hydrogen sulfide worked through nitric oxide-
dependent pathways, but in hypertensive rats, hydrogen sulfide mediated its effects 
through nitric oxide-independent pathways.       
Currently, there is no clear understanding of how hydrogen sulfide mediates its 
protective effects in the intestinal mesenteric vascular bed.  Therefore, prior to hydrogen 
sulfide therapy being used in a clinical setting, the downstream pathways of this novel 
treatment must be further elucidated.  
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Figure 2. Proposed post-translational H2S Modification of eNOS. H2S S-
sulfhydration of eNOS at Cys443 to stabilize eNOS dimers. This in turn leads to 
increased NO production and decreased superoxide generation, both of which are 
essential to maintain normal endothelial functions. ([18] Adapted from Altaany et al. Sci 
Signal, 2014. 7(342): p. ra87) 
 
 
1.4 Impact as a Treatment for Ischemia 
In the United States alone, there are over 47,000 cases of bowel ischemia per year 
[22]. This accounts for an annual cost upwards of over 600 million [22]. Currently, early 
diagnosis is critical with mortality increasing significantly following intestinal infarction. To 
this end, duration of symptoms is predictive of mortality with patients having <12 hours of 
symptoms found to have a mortality rate of 0-17%, patients with symptoms for <24 hours 
having a mortality rate of 44-57% and patients with symptoms for >24 hours having 
mortality rates as high as 73-95%[23].  
Current treatment therapies include embolectomy, revascularization, and resection. 
To date however, there have been no innovative treatment modalities aimed at 
recovering the infarcted bowel. Therefore, a novel therapeutic treatment is essential to 
aid in improving outcomes in this patient population. In this regard, the use of hydrogen 
sulfide (H2S) has recently been identified as a potential therapeutic strategy for 
gastrointestinal disease. 
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1.5 Purposes and Aims of Studies 
Although the exact mechanisms of H2S therapy is not entirely understood, there is a 
significant amount of literature confirming the therapeutic benefits of H2S in the setting of 
I/R injury. Approaching this project, we primarily sought to determine if H2S would 
ameliorate intestinal I/R injury. Furthermore, additional questions had stemmed from 
how little we know about the exact mechanisms of action.  
Currently, there is no clear understanding of how hydrogen sulfide mediates its 
protective effects in the intestinal mesenteric vascular bed.  Therefore, prior to hydrogen 
sulfide therapy being used in a clinical setting, the downstream pathways of this novel 
treatment must be further elucidated. We hypothesized that: 1) H2S would improve post-
ischemic survival, mesenteric perfusion, intestinal mucosal injury scores, and intestinal 
inflammation more effectively compared to vehicle following intestinal I/R, and 2) the 
benefits of H2S therapy would be mediated through endothelial nitric oxide synthase-
dependent pathways. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Murine Intestinal Ischemia-Reperfusion Model 
Experimental protocols and animal use were approved by the Indiana 
University Institutional Animal Care and Use Committee. Wild-type adult male mice 
(C57BL/6J, Stock No: 00664, 8-12 weeks/20-30g Jackson Laboratory, Bar Harbor, ME) 
and eNOS KO mice (B6.129P2-Nos3tm1Unc/J, Stock No: 002684, 8-12 weeks/20-30g; 
Jackson Laboratory, Bar Harbor ME) underwent at least 48 hours of acclimation to the 
new environment prior to experimentation. Mice were provided normal chow and water 
and kept in 12 light/12 dark cycle housing.  
 Mice were anesthetized using 3% isoflurane followed by maintenance at 1.5% 
isoflurane in oxygen. A heating pad was used to achieve temperature homeostasis and 
the abdomen was prepped using a hair removal lotion followed by sterile preparation 
with 70% ethanol and betadine (Figure 3). To account for intra-operative fluid losses, 
one milliliter of 0.9% normal saline was injected subcutaneously pre-operatively. All 
animals were given analgesia (1mg/kg buprenorphine and 5mg/kg carprofen) by 
subcutaneous injection pre-operatively.   
 Under sterile conditions, a midline laparotomy was performed and the intestines 
were eviscerated. The base of the superior mesenteric artery was identified and 
clamped using an atraumatic microvascular clamp. The intestines were then placed 
back into the abdominal cavity and the abdomen was temporarily closed using silk 
suture to prevent evaporative losses. Following 60 minutes of intestinal ischemia, the 
abdomen was reopened and the atraumatic clamp was removed. The abdominal fascia 
and skin were then closed in a two-layer fashion with silk suture. Prior to complete 
abdominal closure the animals underwent intraperitoneal injection with 250µL of 
phosphate buffered saline (vehicle control), or 250µL of sodium hydrosulfide (NaHS) at 
doses of 2 nmol/kg (1.12x10-4mg/kg) or 2µmol/kg (1.12x10-1mg/kg) in PBS. Triple 
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antibiotic ointment was applied to the abdominal incision following complete closure. 
Following surgery, animals were placed in a cage on a heating pad and allowed to 
awaken. Once fully recovered, animals were returned to animal housing.  
 
Figure 3. Murine Ischemia Reperfusion Injury Model  
 
2.2 Survival Analysis 
Animals assigned to the survival protocol were monitored twice daily for 7 days 
following surgery for death, pain, and incisional complications. End points of analysis 
included animal death or when Laboratory Animal Resource Center veterinarians felt 
animals were suffering and needed to be euthanized. Survival curves were created 
based on these end points. Remaining mice were euthanized with isoflurane overdose 
and cervical dislocation at completion of the 7 day designated time course.   
 
 
 
 
 
 
7 
2.3 Laser Doppler Imaging Analysis 
Animals were assigned to the perfusion protocol (N=10 per vehicle group, 8 per 
each NaHS treated group) as follows: 1) WT IR+vehicle, 2) WT IR+2 nmol/kg NaHS, 3) 
WT IR+2 µmol/kg NaHS, 4) eNOS KO IR+vehicle, 5) eNOS KO IR+2 nmol/kg NaHS, 
and 6) eNOS KO IR+2 µmol/kg NaHS. Perfusion was analyzed using a Laser Doppler 
perfusion Imager (LDI; Moor Instruments, Wilmington, DE; Figure 4). Images were 
acquired at baseline, at the initial clamping of the superior mesenteric artery, and 24 
hours after recovery. A region of interest was created around the entirety of exposed 
intestines to obtain a flux mean perfusion within this region.  Three images were 
acquired at each time point and averaged.  Perfusion data were expressed as a 
percentage of baseline (mean±SEM).  After the 24-hour recovery analysis, animals 
were euthanized with isoflurane overdose and cervical dislocation, and intestinal 
tissues were explanted for further analyses.  
 
 
Figure 4. Intestinal Perfusion by Laser Doppler Imager. 
 
2.4 Histological Analysis 
Intestinal tissues were harvested following euthanasia of experimental groups. 
Terminal ileums were then fixed using 4% paraformaldehyde with subsequent 
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dehydration in 70% ethanol. Intestines were paraffin-embedded, sectioned, and 
subsequently stained with hematoxylin and eosin. A histological scoring method of 
intestinal damage was used as previously described: 0, no damage; 1, subepithelial 
space at the villous tip; 2, loss of mucosal lining at the villous tip; 3, loss of less than half 
of the villous structure; 4, loss of more than half of the villous structure; and 5, 
transmural necrosis [24] [25]. All histological sections were evaluated by two blinded 
authors (ARJ, NAD) and scores were averaged.  
2.5 Inflammatory Cytokines 
Following euthanasia, mouse intestinal tissues designated for protein analysis 
were harvested, snap frozen in liquid nitrogen and stored at -80ºC. Once ready to use, 
intestines were thawed and homogenized in RIPA buffer (Sigma, St. Louis, MO) with 
phosphatase and protease inhibitors (1:100 dilution, Sigma, St. Louis, MO) using a 
Bullet Blender tissue homogenizer (Next Advance, Averill Park, NY). Following 
homogenization, samples were centrifuged at 12,000 rpm to pellet extraneous tissue 
and supernatants were collected and placed into fresh Eppendorf tubes. Total protein 
concentration was quantified with the Bradford assay using a spectrophotometer 
(VersaMax microplate reader; Molecular Devices, Sunnyvale, CA).  
Murine intestinal levels of interleukin 6 (IL-6), interleukin 9 (IL-9), interleukin 10 
(IL-10), C-X-C ligand 10 (IP10), macrophage inflammatory protein 2 (MIP-2), 
granulocyte-colony stimulating factor (G-CSF), macrophage inflammatory protein-1 
alpha (MIP-1α), eotaxin, vascular endothelial growth factor (VEGF), fibroblast growth 
factor-2 (FGF-2), hepatocyte growth factor (HGF), and C-X-C ligand 1 (KC) were 
quantified using a Bio-Plex 200 multiplex beaded assay system (Bio-Rad, Hercules, Ca) 
with customizable multiplex plates for murine inflammatory cytokines (Millipore, Billerica, 
MA). Assays were performed at 1:20 dilution according to the manufacturer’s 
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instructions and are reported in nanograms of cytokine per gram of total intestinal protein 
(mean±SEM).  
2.6 Statistical Analysis 
All statistical analysis was performed using GraphPad Prism 7 (GraphPad 
Software, La Jolla, CA). Statistical significance for the survival studies was assessed by 
the Mantel-Cox log rank test and the Gehan-Breslow-Wilcoxon test. Perfusion, histology 
and cytokine analysis were reported as the mean±SEM and compared using the Mann-
Whitney U test for nonparametric variables.  P-values less than 0.05 were considered 
statistically significant.  
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CHAPTER THREE: RESULTS 
3.1 H2S Improves Survival Following Intestinal I/R Injury 
NaHS promoted significant differences in survival based on the dose utilized. 
Survival was significantly improved in mice treated with low dose NaHS (2 nmol/kg, 
83.3%) compared to mice that received vehicle control (40%, p=0.03, Figure 5). No 
difference was found between the 2 nmol/kg and 2 µmol/kg NaHS treated groups 
(p=0.68). Mice treated with 2 mmol/kg NaHS died immediately following intraperitoneal 
injection compared to vehicle control and did not awake from anesthesia (0%, p<0.005). 
Therefore, this higher dose was not used for further experiments. 
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Figure 5. Dose Response Kaplan-Meier plots for 7 day survival after I/R injury. 
There was significantly improved survival following treatment with low dose NaHS (2 
nmol/kg, p=0.03), and significantly worse survival compared to vehicle with the 
2mmol/kg NaHS therapy (2mmol/kg, p=0.005) following intestinal I/R.  Although use of 
the 2µmol/kg NaHS dose had no statistically significant difference from vehicle, it also 
had no statistically significant difference from the 2 nmol/kg group (*=p<0.05 versus 
vehicle). 
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3.2 H2S Improves Intestinal Perfusion Following I/R Injury Through eNOS 
Dependent Pathways 
Intestinal perfusion was compared in treatment groups at 24 hours following IR 
injury (Figure 6).  Low-dose and high-dose NaHS treatment promoted significantly 
improved post-ischemic perfusion levels (78.3±7.3%, 63.4±7.2%) compared to vehicle 
(26.4±5.3%; p=0.0002, p=0.003 respectively) in WT animals assessed at 24 hours 
following injury. Conversely, in eNOS KO mice, perfusion was similar among treated and 
untreated groups, and no significant differences were found between vehicle 
(34.4±6.6%), 2 nmol/kg NaHS (32.1±6.9%) or 2µmol/kg NaHS (52.7±9.2%) treated 
groups (p=0.72 and p=0.33 respectively). 
 
Figure 6: H2S improves mesenteric perfusion following ischemic injury through 
eNOS dependent pathways. Post-ischemic mesenteric perfusion was significantly 
increased with both low dose and mid-range doses of NaHS in WT animals.  However, 
there were no observed improvements in post-ischemic mesenteric perfusion following 
treatment in eNOS KO animals. (*=p<0.05 versus respective vehicle) 
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3.3 H2S Prevents Mucosal Injury Following I/R Through eNOS Dependent 
Pathways 
Significant sloughing of intestinal mucosa and destruction of the epithelial layer in 
the crypt-villous architecture was seen in PBS vehicle-treated WT groups (3.2±0.30) 
compared to WT mice treated with 2nmol/kg NaHS (1.3±0.25, p<0.0001) or 2µmol/kg 
NaHS (1.6±0.29, p=0.002). No significant improvements were seen in histological injury 
with NaHS therapy in eNOS KO animals (Figure 7). 
 
Figure 7: Histological examination of small intestine following intestinal I/R.  A) 
Representative histology slides of each treatment group (hematoxylin and eosin stain, 
x20) demonstrating improvements in intestinal histology with NaHS therapy in WT 
animals but not in eNOS KO animals.  B) Histological scoring of intestinal specimens (*= 
p<0.05 vs respective vehicle). 
 
 
 
 
13 
3.4 H2S Attenuates the Intestinal Inflammatory Cytokine Response following I/R 
injury  
Intestinal cytokines and growth factors were affected by hydrogen sulfide therapy 
following ischemic injury.  IL-6 was noted to be significantly decreased in WT intestines 
exposed to both 2nmol/kg and 2µmol/kg NaHS, while IL-9, IL-10, VEGF, and FGF-2 
were only lowered by the 2µmol/kg dose of NaHS (Figure 8).  In murine animals with 
eNOS KO, while decreases in IL-9, IL-10, and VEGF were observed, they did not reach 
statistical significance. Interleukin 6  and FGF-2 were the only two cytokines to have a 
significant decreases in chemokine production. IL-6 significantly decreased with 2 
µmol/kg NaHS treatment and FGF-2 significantly decreased with 2 nmol/kg NaHS 
treatment.  HGF was not affected in this model system by NaHS or with eNOS ablation. 
Inflammatory chemokines in the intestinal segments were also affected by NaHS 
following injury (Figure 9).  MIP-1α, eotaxin, and IP-10 were significantly decreased only 
in the 2µmol/kg treated groups, while there was no effect on these factors with the lower 
doses of NaHS in WT intestinal segments.  Levels of MIP-2, GCSF, and KC were 
significantly decreased in intestines with both tested doses of NaHS.  Lastly, when 
evaluating cytokines from NaHS-treated intestines from eNOS KO animals, there were 
no significant differences compared to the vehicle-treated group. 
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Figure 8: Inflammatory cytokines and growth factors are impacted by Hydrogen 
Sulfide therapy following Intestinal I/R.  Intestinal levels of IL-6, IL-9, IL-10, VEGF, 
and FGF-2 are decreased with hydrogen sulfide therapy following intestinal ischemia.  
Hydrogen sulfide decreases in IL-9, IL-10, and VEGF appear to be facilitated by intact 
eNOS, whereas decreases in IL-6 and FGF-2 may work through H2S independent 
pathways.  HGF does not appear to be affected by hydrogen sulfide therapy or ablation 
of eNOS. (*=p<0.05 vs. WT vehicle, #=p<0.05 vs. eNOS KO vehicle) 
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Figure 9: Chemokines are impacted by Hydrogen Sulfide therapy following 
Intestinal I/R.  Intestinal levels of MIP-1α, eotaxin, IP-10, MIP 2, G-CSF, and KC are 
decreased in ischemic intestines following hydrogen sulfide therapy.  Levels of these 
factors were not impacted significantly by genetic ablation of eNOS. (*=p<0.05 vs. WT 
vehicle) 
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CHAPTER FOUR: DISCUSSION & CONCLUSION 
4.1 Discussion 
Intestinal ischemia is a devastating abdominal emergency.  Many times necrotic 
intestine needs to be surgically excised, which can leave patients with an inadequate 
amount of bowel to promote normal nutrient absorption.  Current therapies are 
inadequate at protecting ischemic intestine, and therefore, novel therapies are being 
explored.  Herein we observed that hydrogen sulfide treatment (in the form of NaHS) 
following ischemia and reperfusion injury can provide gastrointestinal protection. These 
beneficial properties appear to be mediated, in part, by endothelial nitric oxide synthase.  
 We observed improvements in survival, mesenteric perfusion, preservation of 
intestinal mucosal integrity and decreased inflammation following ischemic insult. 
However, while we did observe significant benefits with NaHS therapy following 
intestinal ischemia, these beneficial properties were not observed in the absence of 
endothelial nitric oxide synthase. Similarly, Coletta et al. previously reported that H2S-
induced angiogensis requires nitric oxide biosynthesis and inhibition of eNOS abolished 
the H2S-stimulated angiogenic response [26]. Their research suggested that nitric oxide 
and H2S worked synergistically to increase cGMP production, cGMP-dependent protein 
kinase G (PKG) activation, and angiogenesis. Additionally, in their studies the 
vasorelaxant action of H2S also required the presence of endogenously produced nitric 
oxide, further confirming the significant complexity of biological interactions between 
these two gasotransmitters.  
 NaHS clearly impacted survival, although this appeared to be in a reverse dose 
dependent fashion, with higher doses promoting near instantaneous death.  This 
certainly makes sense given that hydrogen sulfide is toxic in high doses.  Other studies 
have corroborated toxic effects on organs at similar millimolar doses used in this study 
[27].  Toxicity is felt to result from inhibition of cytochrome C oxidase in complex IV of the 
17 
electron transport chain, the last complex prior to ATP production [28].  The resulting 
effect is cardiovascular demise with a rapid fall in left ventricular ejection fraction and 
pulseless electrical activity [29].   
However, at more physiologic doses, sulfide ions are donated to complex II of the 
mitochondrial electron transport chain which assists in stimulating ATP production [28].  
In addition, it appears that hydrogen sulfide S-sulfhydrates eNOS at Cys443 which 
promotes dimerization of eNOS and production of nitric oxide [18].  Nitric oxide then 
promotes vasodilation.  In this study, we observed equivalent rates of improvement in 
mesenteric perfusion with the addition of both 2nmol/kg and 2µM/kg NaHS.  These 
improvements in perfusion were lost when eNOS was genetically ablated.  
Intestinal mucosal injury was also improved with NaHS therapy.  Although it is 
possible that H2S can directly preserve intestinal mucosal integrity by limiting 
inflammation and apoptosis [11, 12, 17], it is also equally likely that the main effects of 
hydrogen sulfide therapy are to promote vasodilation [30] and improve mesenteric blood 
flow.  Better intestinal reperfusion after injury in itself will limit further mucosal damage 
and intestinal inflammation.  Furthermore, if the effects of H2S were solely on the 
intestinal epithelium, then knocking out endothelial nitric oxide synthase should not have 
had an effect on host preservation. 
Significant elevations in intestinal chemokines, including macrophage 
inflammatory protein (MIP), eotaxin, and chemokine ligand 10 (IP-10) have been noted 
following intestinal ischemia, and are thought to be responsible for leukocyte 
mobilization to the areas of injured bowel [31, 32].  These cells are responsible for injury 
repair, but also promote inflammation, which may be detrimental to the host.  For 
example, lymphocyte influx is thought to be detrimental to recovery, as lymphocyte 
depleted animals had better outcomes following intestinal ischemia [33].  However, other 
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leukocyte classes may actually promote intestinal recovery by digesting dead cells and 
repairing the extracellular matrix [34].  Additionally, markers of neovascularization have 
been elevated after intestinal ischemia [35, 36].  Neovasculogenesis increases intestinal 
capillary density to restore oxygen balance and nutrient homeostasis to injured bowel. 
In similar fashion, we also appreciated a significant decrease in intestinal 
chemokines.  High dose NaHS (2 µmol/kg) decreased MIP-1α, eotaxin, and IP-10 levels, 
while both low and high-range doses significantly decreased intestinal MIP-2, GCSF, 
and KC levels.  While we observed lower levels of several chemokines in eNOS KO 
animals following NaHS therapy, none of these reached statistical significance. 
Therefore, hydrogen sulfide mediated decreases in all assessed chemokines following 
intestinal ischemia appeared to be dependent on the presence of eNOS.   
We also observed a significant decrease in several inflammatory cytokines and 
growth factors after NaHS therapy.  IL-6, IL-9, IL-10, VEGF, and FGF-2 were all 
decreased after NaHS therapy, although only IL-6 was noted to be decreased at both 
the 2 nmol/kg and 2 µmol/kg concentrations.  HGF was not impacted by NaHS therapy.  
While decreases in IL-9, IL-10, and VEGF appeared to be dependent on functioning 
eNOS, production of IL-6 appeared to also decrease in mid-range dose eNOS KO 
animals, and FGF-2 appeared to decrease in the low-range NaHS treated eNOS KO 
animals.  HGF was also not affected by ablation of eNOS.  These findings would indicate 
that many of the inflammatory factors tested, but certainly not all of them, were impacted 
by the presence of functional eNOS. Based on the data presented herein, we surmise 
that the presence of eNOS promotes hydrogen sulfide mediated improvements in 
vascular tonicity.  Because of better mesenteric perfusion, injured intestines are able to 
recover more effectively and inflammatory cytokines and chemokines are not as 
abundant.   
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4.2 Limitations 
 
 The superior mesenteric artery (SMA) ligation model of intestinal I/R does not 
model clinical intestinal ischemia to its fullest.  Although complete small bowel ischemia 
is possible secondary to SMA thrombus or embolus, the majority of intestinal ischemic 
episodes are due to segmental intestinal ischemia, such as may be seen with adhesive 
bowel obstructions or incarcerated hernias.  Nonetheless, this model mimics the most 
severe form of intestinal ischemia, and therefore, is likely considered the best animal 
model available to test the effectiveness of novel therapies.   
 
4.3 Conclusions 
 
 In conclusion, hydrogen sulfide appears to be a novel therapeutic agent for the 
treatment of intestinal ischemia and reperfusion injury.  The beneficial effects of 
improved mesenteric perfusion, histological injury, and inflammatory cytokine and 
chemokine modulation appear to be mediated through endothelial nitric oxide synthase.  
Additional modes of delivery, including inhaled delivery systems, need to be tested with 
this model to determine best clinical application.  These factors, as well as the effects of 
hydrogen sulfide on long term survival and neurodevelopment, need to be assessed 
prior to widespread clinical implementation. 
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